Home
Drugs
Daratumumab
Clinical Trials

Clinical Trials Related to Daratumumab

Related studies linked through entity extraction aliases.

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Status: COMPLETED
Phase: PHASE3

Pan Tumor Rollover Study

Status: RECRUITING
Phase: PHASE2

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Status: WITHDRAWN
Phase: PHASE2

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE4

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Status: COMPLETED
Phase: PHASE4

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Status: WITHDRAWN
Phase: PHASE1/PHASE2

A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

Status: COMPLETED
Phase: PHASE2

Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

Status: UNKNOWN
Phase: PHASE2

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Status: TERMINATED
Phase: PHASE2

Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

Status: UNKNOWN
Phase: PHASE2

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Status: COMPLETED
Phase: PHASE3

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Status: COMPLETED
Phase: PHASE3

Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

Status: TERMINATED
Phase: PHASE2

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Status: WITHDRAWN
Phase: PHASE1

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2